2008
DOI: 10.1016/j.rmed.2008.04.009
|View full text |Cite
|
Sign up to set email alerts
|

The economic burden of chronic obstructive pulmonary disease (COPD) in a U.S. Medicare population

Abstract: In this U.S. Medicare managed care population, COPD posed a substantial burden in terms of both respiratory-related and total healthcare costs. A comparison of these cost-of-illness estimates to those for elderly COPD patients in other countries would be of great interest, given the increasing age of populations in most Western countries.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

5
75
1

Year Published

2010
2010
2017
2017

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 102 publications
(81 citation statements)
references
References 18 publications
5
75
1
Order By: Relevance
“…Chronic obstructive pulmonary disease (COPD) is a common chronic illness with an associated cost 1,2 . Inadequate literacy skills are common and associated with increased risk for mortality, hospitalization, and poor disease control [3][4][5][6][7] .…”
Section: Introductionmentioning
confidence: 99%
“…Chronic obstructive pulmonary disease (COPD) is a common chronic illness with an associated cost 1,2 . Inadequate literacy skills are common and associated with increased risk for mortality, hospitalization, and poor disease control [3][4][5][6][7] .…”
Section: Introductionmentioning
confidence: 99%
“…The yearly cost of COPD to Medicare is high, with an estimated $4 billion spent in COPD-related hospitalizations alone (2). Most of this spending is incurred on repeat visits to the emergency department (ED) and rehospitalizations after an acute exacerbation of COPD (AE-COPD) (3)(4)(5). For older beneficiaries hospitalized with an AE-COPD, the estimated 30-day all-cause rehospitalization rate is as high as 20 to 23% (6,7).…”
mentioning
confidence: 99%
“…1 Diagnosis of COPD is usually made on the basis of medical history taking, physical examination, and results from pulmonary function test. 2 Worldwide, the prevalence of COPD is 4-10% of all population. 3,4 The World Health Organization (WHO) has ranked COPD as the fourth leading cause of death.…”
Section: Introductionmentioning
confidence: 99%
“…6 The COPD is mostly accompanied by comorbidities that can impact patients' prognosis, change the effectiveness of COPD therapy, cause potentially dangerous therapeutic interactions and increase patients' expenses in treating the disease. 2,[7][8][9] The definition of comorbidity is the presence of one or more diseases or health conditions in an individual at a given time. 10 Comorbidity is different from complication.…”
Section: Introductionmentioning
confidence: 99%